DE69934096D1 - Zusammensetzungen und methoden zur wundheilung - Google Patents

Zusammensetzungen und methoden zur wundheilung

Info

Publication number
DE69934096D1
DE69934096D1 DE69934096T DE69934096T DE69934096D1 DE 69934096 D1 DE69934096 D1 DE 69934096D1 DE 69934096 T DE69934096 T DE 69934096T DE 69934096 T DE69934096 T DE 69934096T DE 69934096 D1 DE69934096 D1 DE 69934096D1
Authority
DE
Germany
Prior art keywords
wound healing
compositions
methods
wounds
mammals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69934096T
Other languages
English (en)
Other versions
DE69934096T2 (de
Inventor
Ellen Heber-Katz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wistar Institute of Anatomy and Biology
Original Assignee
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Institute of Anatomy and Biology filed Critical Wistar Institute of Anatomy and Biology
Publication of DE69934096D1 publication Critical patent/DE69934096D1/de
Application granted granted Critical
Publication of DE69934096T2 publication Critical patent/DE69934096T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
DE69934096T 1998-02-13 1999-02-12 Zusammensetzungen und methoden zur wundheilung Expired - Fee Related DE69934096T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7473798P 1998-02-13 1998-02-13
US74737P 1998-02-13
US9793798P 1998-08-26 1998-08-26
US97937P 1998-08-26
US10205198P 1998-09-28 1998-09-28
US102051P 1998-09-28
PCT/US1999/002962 WO1999041364A2 (en) 1998-02-13 1999-02-12 Compositions and methods for wound healing

Publications (2)

Publication Number Publication Date
DE69934096D1 true DE69934096D1 (de) 2007-01-04
DE69934096T2 DE69934096T2 (de) 2007-07-05

Family

ID=27372536

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69934096T Expired - Fee Related DE69934096T2 (de) 1998-02-13 1999-02-12 Zusammensetzungen und methoden zur wundheilung

Country Status (8)

Country Link
US (2) US6538173B2 (de)
EP (1) EP1053309B1 (de)
JP (1) JP2002503460A (de)
AT (1) ATE346147T1 (de)
AU (1) AU2672099A (de)
CA (1) CA2319700C (de)
DE (1) DE69934096T2 (de)
WO (1) WO1999041364A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225019A1 (en) * 2002-05-30 2003-12-04 Freier Susan M. Notch1 inhibitors for inducing apoptosis
US20090060988A1 (en) * 1999-10-05 2009-03-05 Kang Ting Nell-1 enhanced bone mineralization
EP1127576A1 (de) * 2000-02-23 2001-08-29 Switch Biotech Aktiengesellschaft Verwendungen von NM23-Polypeptiden bei Haut- und Darmerkrankungen
WO2001087907A2 (en) * 2000-05-17 2001-11-22 Genaissance Pharmaceuticals, Inc. Haplotypes of the osm gene
DE10038111A1 (de) * 2000-08-04 2002-03-07 Switch Biotech Ag Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren einer Familie von G-Protein gekoppelten Rezeptoren zur Diagnose oder Behandlung von Erkrankungen, beispielsweise Hautkrankheiten, sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
AT500019B1 (de) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm Verwendung in vitro des transkriptionsfaktors nak-1 oder von nak-1 regulierten genen zur diagnose von entzündlichen und malignen erkrankungen
CA2516945A1 (en) * 2003-02-24 2004-09-02 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for spinal cord injury comprising interleukin-6 antagonist
EP2256198A1 (de) * 2004-06-14 2010-12-01 Galapagos N.V. Identifizierungsverfahren und Verbindungen für die Behandlung degenerativer und entzündlicher Erkrankungen
US7247457B2 (en) * 2005-04-26 2007-07-24 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Detection and identification of enteroviruses by semi-nested amplification of the enterovirus VP1 protein
CA2665717C (en) * 2005-10-25 2016-01-19 Women's & Children's Health Research Institute Methods and compositions comprising a flightless i antagonist for modulating wound repair
AU2006308431B2 (en) * 2005-10-25 2011-11-10 Adelaide Research & Innovation Pty Ltd Methods and compositions for modulating wound repair
WO2011066175A1 (en) * 2009-11-25 2011-06-03 Nestec S.A. Nutritional compositions including a high protein component and exogenous nucleotides
US20130217594A1 (en) * 2010-10-29 2013-08-22 Institute for Cancer Research d/b/a The Research Center of Fox Chase Cancer (Fox Chase Cancer Methods for screening compounds for capability to inhibit premalignant squamous epithelial cell progression to a malignant state
US20200263173A1 (en) * 2017-09-13 2020-08-20 The Children's Medical Center Corporation Compositions and methods for treating transposon associated diseases
US20230338529A1 (en) * 2020-08-06 2023-10-26 The Children's Medical Center Corporation Compositions for altering a microglial cell, and methods of use therefore

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233558T2 (de) * 1991-11-20 2006-07-27 Innogenetics N.V. Keratinozyt-abstammende Granulate zur Verwendung als wundheilendes Mittel
WO1997033980A1 (en) 1996-03-15 1997-09-18 The General Hospital Corporation Transgenic animals having a disrupted endothelial nitric oxide synthase gene and methods of use
WO1998020112A1 (en) * 1996-11-07 1998-05-14 The Wistar Institute Of Anatomy And Biology Sparc-deficient transgenic mice

Also Published As

Publication number Publication date
CA2319700A1 (en) 1999-08-19
US6538173B2 (en) 2003-03-25
AU2672099A (en) 1999-08-30
US20030037345A1 (en) 2003-02-20
US20030229911A1 (en) 2003-12-11
WO1999041364A3 (en) 1999-12-23
WO1999041364A2 (en) 1999-08-19
US7473414B2 (en) 2009-01-06
JP2002503460A (ja) 2002-02-05
EP1053309A1 (de) 2000-11-22
DE69934096T2 (de) 2007-07-05
CA2319700C (en) 2011-09-20
EP1053309B1 (de) 2006-11-22
ATE346147T1 (de) 2006-12-15

Similar Documents

Publication Publication Date Title
ATE346147T1 (de) Zusammensetzungen und methoden zur wundheilung
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE295735T1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DE69831566D1 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
BR0107943A (pt) Sìtios de entrada de ribossoma internos sintéticos e métodos de identificar os mesmos
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE60228278D1 (de) Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
ATE275400T1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
DE60216281D1 (de) Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
DE69902520T2 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
DE60012718D1 (de) Prognose von ptp lar vermittelten krankheiten
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee